Viz.ai

Enterprise licensing to health systems and hospitals. No public pricing or individual access.

Enterprise and pharmaceutical partner licensing. No public pricing or individual access.

Medical imaging data and patient information processed under HIPAA BAA with medical device security standards. FDA cleared for specific clinical indications. Review indication-specific clearance documentation.

Digital pathology slide data processed under HIPAA BAA. FDA clearance for clinical use is indication-specific — review regulatory status for each intended use.

• ✓FDA clearance and published clinical evidence validate AI accuracy for critical cardiovascular indications
• ✓Parallel specialist notification can reduce time to treatment by 30-60 minutes in stroke cases
• ✓1,400+ hospital deployments provide strong clinical reference evidence
• ✓Care coordination platform handles team logistics beyond just detection alerts

• ✓Demonstrable accuracy in specific cancer diagnosis tasks on large pathology slide datasets
• ✓Pharmaceutical partner programme with BMS, AstraZeneca, and Gilead validates clinical credibility
• ✓Consistent quantification across large sample sets improves on inter-pathologist variability
• ✓FDA-cleared tools for specific clinical indications

• ✕Enterprise hospital licensing only — no individual or clinic access
• ✕Clinical benefit dependent on implementation and hospital workflow integration quality
• ✕FDA clearance is indication-specific — review which conditions are cleared for clinical use

• ✕Enterprise and pharmaceutical partner model — not accessible to individual pathology labs
• ✕Regulatory clearance is indication-specific — clinical use requires FDA-cleared indications only
• ✕ROI case requires high-volume pathology operation or significant clinical trial programme